Sterile tissues of human subjects free from infection and malignancy were assessed for an antigen that cross-reacts with the enterobacterial common antigen (ECA). Extracts of heated homogenates (HE) and ethanol-soluble (ES) fractions of liver, kidney, muscle, and heart tissues were examined for their capacities to react with ECA antibodies, as measured by hemagglutination procedures, and to elicit ECA humoral antibodies in rabbits. Both HE and ES extracts ofhuman liver and kidney tissues specifically inhibited ECA hemagglutination. However, ES fractions of HE preparations demonstrated significantly greater inhibition than their HE sources. In addition, both liver and kidney ES fractions primed rabbits for a rapid and specific secondary ECA humoral response to a single administration of ECA. The cross-reactivity noted between human tissues and ECA cannot be attributed to indigenous microorganisms present in the tissues, as subcultures oftissue homogenates were always sterile. Moreover, preliminary experiments with human fetal subjects, devoid of microbial flora, yielded similar results.
Recent findings from this laboratory (6, 7) have shown that crude supernatant fluids and ethanol-soluble (ES) fractions ofheated homogenates (HE) of mouse kidney and liver tissues contain an antigen that shares characteristics in common with the enterobacterial common antigen (ECA). These observations become clinically significant when considered with reports that ECA, a heterogenetic antigen of the family Enterobacteriaceae, has been implicated in the pathogenesis of ulcerative colitis (3, 12, 19) and the renal lesions of pyelonephritis (9) due to gram-negative infections.
ECA, first described by Kunin et al. (11) , is found in the supernatant fluids of enterobacterial cultures and readily adsorbs to the membranes of erythrocytes for passive hemagglutination by ECA antibodies. However, with the exception of Escherichia coli 014 and R-1 and R-4 core types (11, 26) , ECA has been shown to be non-immunogenic in the presence of its own or heterologous lipopolysaccharide (LPS) or lipid A (23, 27) . Ethanol-soluble ECA, essentially free from LPS, is capable of engendering significant ECA hemagglutinin levels in rabbits (17) , human subjects (8) , and, to a lesser degree, guinea pigs (15) . Although LPS appears to suppress humoral ECA antibody formation, i.e., animals given a mixture of ECA and LPS or lipid A fail to produce significant ECA hemagglutinin titers, these same animals are immunologically primed and will mount a secondary humoral response to subsequent challenge with minimal amounts of ethanolsoluble ECA (27, 28) . Earlier studies (3, 12, 19) with extracts ofE. coli 014 and colon tissue from gnotobiotic rats have shown that these preparations will react with both rabbit antisera to E. coli 014 and sera from ulcerative colitis patients. Recently, Rabin and Rogers (21) have shown that liver, kidney, duodenum, and colon share a crossreactive tissue antigen that may be implicated in the chronic active hepatitis that is so often seen in patients suffering from such inflammatory intestinal diseases as ulcerative colitis and Crohn's disease (5, 9) . In addition, Holmgren et al. (9) have reported an immunological relationship between E. coli serogroups 014 and 02 and human kidney and colon tissues. Although these investigators, using both bacteria-and tissue-derived antisera, could not demonstrate fused precipitin lines of identity among all of the preparations, the position and shape of the lines observed implicated the presence ofa common antigen, presumably ECA. However, absorption of their tissue-and E. coli-derived test sera with human liver antigen failed to remove any ECA activity. The existence in tissue of an antigen that is also shared by members of the 36 normal enterobacterial flora of the gut may be a factor in the pathogenesis of chronic inflammatory diseases such as ulcerative colitis, chronic liver hepatitis, or chronic pyelonephritis. The objective of this report is to show that such a cross-reactive antigen does exist and that its specificity is similar to that of ECA.
MATERIALS AND METHODS
Bacterial strains and antigens. Smooth strains of E. coli serogroups 014, 0111, and 086 and Salmonella typhimurium C5S were selected from our stock culture collection. The preparation ofbacterial antigens, unless otherwise specified, including supernatant fluids of heated bacterial suspensions (HKS) and ES fractions, have been previously described (23) . These preparations were used in the hemagglutination inhibition tests described below and to engender ECA and 0 antisera in rabbits.
Preparation of human tissue antigens. Human adult and adolescent subjects, who died suddenly from traumatic injuries, were autopsied within 24 h of expiration. Kidney, liver, and muscle tissue samples were removed aseptically and examined grossly and histologically for signs of disease or dysfunction. In all, suitable samples were obtained from 20 subjects.
Each sample was weighed and homogenized in phosphate-buffered saline (PBS) (pH 7.2) (1.0 g of tissue per 1.8 ml of PBS) in a Waring blender (Waring Products, Hartford, Conn.). Samples of the freshly homogenized material were inoculated on sheep blood agar and Endo agar (Difco Laboratories, Detroit, Mich.) and into beef infusion broth (Difoo) to confirm sterility. The tissue homogenates were immediately transferred to a 100°C water bath for 30 min and then centrifuged at 23,500 x g for 15 min at 40C; HE were decanted and stored at -20°C. Materials demonstrating microbial growth after culture were discarded.
The ES fractions of kidney, liver, and muscle tissues were prepared by an adaptation of the method described by Suzuki et al. (23) for preparing ES fractions of bacteria. Briefly, to each volume of tissue HE was added 8.5 volumes of 95% ethanol. This mixture was kept at room temperature for 18 to 20 h and centrifuged for 15 min at 23,000 x g (40C).
The water-clear ES fraction was decanted and flashevaporated to dryness. The dried sediment was dissolved in sterile distilled water to one-third of its original volume and dialyzed against large volumes of PBS for 24 h at 4°C. The resulting material was stored at -20°C.
Kidney, liver, and heart tissue samples of human fetuses obtained from saline-and prostaglandin-induced abortions were used as sources of gnotobiotic human tissue. Fetuses obtained within 24 h after abortion were aseptically opened, and the appropriate tissues were removed and stored at -20°C. Each of the tissue samples was prepared as an ES fraction as previously described with adult and adolescent tissue; i.e., each organ was weighed and homogenized in PBS (1.0 g of tissue per 2.0 ml) in a Tefloncoated tissue grinder (Pyrex) with a motorized pestle (2,000 rpm). Each of these homogenates was assessed for bacterial contamination by using the same criteria as those employed for adult and adolescent tissue. Homogenates ofthe same tissue were processed as either individual or pooled samples, dependent upon the volume of material available, and prepared as ES fractions by the method previously described.
Experimental animals. New Zealand rabbits (female, 2.5 to 3.5 kg; Richards Rabbitry, Asheville, N.Y.) were individually housed in metal cages and maintained on a standard rabbit diet (Charles River, Syracuse, N.Y.) and water ad libitum.
Preparation of ECA antisera. Anti-ECA antisera were obtained from New Zealand rabbits that were injected with one of the following preparations: E. coli 014 HKS, E. coli 0111 ES, E. coli 086 ES, or S. typhimurium ES. Each rabbit received 1 ml of antigen intravenously (i.v.) on days 0, 3, 6, 9, and 16. Sera were obtained on days 0, 12, 20, and 23 and titrated for ECA hemagglutinins by a procedure previously described (15) .
Assay of human tissues for cross-reacting antigen. The presence of a cross-reacting antigen in human tissue was determined by an adaptation of a method previously described to demonstrate the presence and specificity of ECA in enterobacterial extracts (23) and mouse tissues (6, 7) . HE or ES fractions of tissue homogenates were used to inhibit ECA hemagglutination and to passively modify sheep and rabbit erythrocytes for agglutination by ECA antisera.
Modification of erythrocytes with human tissue extracts for ECA hemagglutination. HE and ES extracts of human liver and kidney were used to passively modify erythrocytes for ECA hemagglutination as previously described by Suzuki et al. (23) . Active modifications with chromium chloride as described by Baker et al. (2) and chromium chloride with piperazine buffer (20) were also attempted. In addition, the effects of our tissue preparations on the modifying capacity of bacteria-derived ECA were examined. To this end, individual or combined preparations of human kidney and E. coli 0111, as described below, were used to passively modify and/or inhibit ECA hemagglutination with anti-S. typhimurium, using a microtiter technique (15) .
E. coli 0111 HKS, E. coli 0111 ES, human kidney HE, and human kidney ES preparations were obtained by procedures previously described. An HKS mixture of E. coli 0111 and human kidney was prepared by combining equal volumes of human kidney homogenate and a viable suspension of E. coli 0111 and heating the mixture in a 1000C water bath for 1 h. The mixture was centrifuged at 23,500
x g for 20 min (4C), and the supernatant fluid was decanted. A portion of this fluid was extracted with ethanol by the same procedure used for making the bacterial or tissue ES preparations described above.
Assay of human tissues for cross-reacting immunogen. Rabbits used in assessing the immunogenicity of the human tissue preparations were divided into three groups. ES tissue extracts of human kidney and liver were pooled, dialyzed against distilled water for 24 h, lyophilized, and suspended in PBS to a final concentration of 3 mg/ml. Human kidney ES was administered to one group of eight rabbits, and human liver ES was administered to a second group of eight rabbits. To the remaining group of six animals, an equivalent volume of PBS was given as a control. Immunization consisted of three i.v. injections (1.0 ml) of either human liver or kidney ES, or PBS, on days 0, 5, and 10. On day 20, E. coli 0111 ES (1.0 ml) was injected i.v. into the experimental and control animals. Whole blood samples were collected prior to immunization and on days 10, 15, 20, 23, 26, and 30. Separated sera were maintained at -20°C until thawed immediately prior to titration for ECA, E. coli 0111 0, and Forssman hemagglutinins.
Statistical analyses. Correlation analysis was performed by obtaining the product-moment (Pearson r) correlation coefficient of the parameters being tested. The relative amount of inhibitory capacity of a preparation was measured as the ECA hemagglutinin titer without inhibitor to the titer with inhibitor. Liver and kidney ES extracts from human subjects (male and female, 6.5 months to 59 years of age) demonstrated a marked variation in inhibiting ECA hemagglutination (Table 2) . A 4-to 64-fold reduction in titers was observed, and no single specimen was devoid of activity. Correlation and differential analyses of the relative amount of inhibition seen with each tissue sample and such physical variables as sex, weight, and height were insignificant. cross-reactive antigen in a subject's liver as compared with the relative amount in the same subject's kidney were noncorrelative.
Aborted human fetuses (male and female, 10 to 22 cm in length) were employed as a source of gnotobiotic human tissue. Due to the insufficient size of the individual tissue samples, tissue homogenates of like organs were pooled and prepared as ES fractions. In addition, three fetal heart specimens were tested for their ca-pacity to inhibit ECA hemagglutination. The results are presented in Table 3 . The four pooled samples of fetal kidney reduced ECA hemagglutinin titers 16-or 32-fold, and the five pooled samples of fetal liver reduced the hemagglutinin titers 8-to greater than 128-fold. Of interest was the observation that each ofthe three fetal heart specimens failed to reduce the titers of these same ECA antisera.
Not shown in Tables 1 to 3 are data supporting the ECA specificity of human liver and kidney preparations. Liver (3 mg/ml) and kidney (5 with E. coli 0111 ES, all groups mounted a humoral response that persisted for the remainder of the experiment. However, unlike the control animals (PBS), which demonstrated low ECA hemagglutinin titers 3 days after the booster, animals primed with either kidney or liver ES appeared to mount a secondary humoral response after immunization with ECA. There was a significant and sudden rise in titer, which slowly fell and persisted through the remainder of the experiment. Examination of the sera from all groups failed to demonstrate a change in Forssman antibody titer or the presence ofE. coli 0111 0 antibodies (no titers were >10). DISCUSSION The presence in tissue of an antigen that cross-reacts with ECA may account, at least in part, for the etiology or pathology of ulcerative colitis (3, 17, 19) and pyelonephritis (9) . This conjecture is supported by the present data, which reveal striking antigenic similarities between normal human tissue (kidney and liver) and ECA.
Preliminary experiments with human kidney, liver, striated muscle, and fetal heart tissue revealed that only extracts of kidney and liver specifically inhibited ECA hemagglutination. Moreover, ES fractions of these same crude extracts were two-to fourfold more inhibitory. This further reduction ofECA hemagglutinin titers by ethanol extracts suggests the presence in crude preparations of an inhibitor or factor that is neutralized or precipitated by ethanol. It is of interest that a similar factor was observed in the liver tissues of Swiss white and C57BL/6Ha strains of mice (6) . The presence of such a factor may explain why Aoki and co-workers (1) could not demonstrate ECA in normal mouse and human kidneys by indirect immunofluorescence with rabbit anti-ECA antisera or why Holmgren et al. (9) failed to detect an ECA cross-reactive antigen in human liver tissue. In addition, this factor may block the recognition of the cross-reactive antigen as "self" and allow for the production of significant levels of anti-ECA humoral antibodies by healthy individuals (3, 8) .
It is of interest that each of the normal adolescent and adult subjects studied exhibited an ECA cross-reactive antigen in extracts of both their liver and kidneys. Furthermore, the appearance of this specific antigen in human fetal liver and kidney preparations provides evidence that the results obtained reflect a native tissue antigen and not the deposition of bacteria or bacterial products from some previous or sequestered enteric infection.
Although our data support cross-reactivity between tissue and ECA, we were not able to demonstrate antigenic identity by co-precipitation in agarose gels with anti-ECA antisera. However, Whang and co-workers (25) (27, 28) and more recently with mouse liver and kidney preparations (6, 7) . The former investigators demonstrated that a mixture of LPS and ECA engendered immunological memory without the production of detectable humoral antibodies. Furthermore, the finding that both the experimental and control animals did not exhibit a change in Forssman antibody levels or a marked change in E. coli 0111 0 titers clearly demonstrates that the priming effect was ECA specific and not due to an anamnestic response as a result of the immunization with tissue extracts. The existence of heterogenetic or cross-reactive antigens between microorganisms and mammalian tissues and their possible role in the host-parasite relationship have been documented (13, 29) . In this regard, a number of investigators have provided evidence that infections by microorganisms containing crossreactive antigens may induce autoimmune reactions such as those speculated between human heart muscle and group A streptococci (10, 29) , glomeruli, and nephritogenic streptococci (15) and rat muscle and Mycoploasma sp. (4) . In addition, the presence of cross-reactive antigens may be responsible for the immunological unresponsiveness of hosts to certain infectious processes (22) .
Workers (3, 12, 21) studying ulcerative colitis have demonstrated that colon tissue andE. coli contain a cross-reactive antigen and that the specificity of the cross-reaction is probably ECA. The finding by Bull and Ignaczak (3) that peripheral lymphocytes of ulcerative colitis patients produce macrophage inhibition factor in the presence of ECA has provided additional evidence that the antigenic specificity of the cellular autoimmune process is to a tissue antigen with ECA-like specificity. Furthermore, several investigators have shown a significant association of inflammatory diseases of the intestine with chronic active hepatitis and/or renal lesions and kidney dysfunction (5, 9) . These investigators and others (21) have alluded to an auto-immune reaction to a shared antigen. Our data with human kidney and liver and ECA support and extend the hypothesis of Holmgren et al. (9) that the pathology noted in ulcerative colitis and chronic pyelonephritis patients is due to an autoimmune reaction precipitated by the host's response to a common antigen found in the normal flora or the infecting organism. The ability of healthy human subjects to escape these diseases may be attributed to their immunocompetence in recognizing selfantigens and/or the presence of an ethanolinsoluble blocking factor. Furthermore, the presence of a cross-reactive antigen between certain human tissues and enteric organisms supports the tenet of Rowley and Jenkin (22) that some infections result from the host's inability to react to an offending microorganism that it recognizes as self. In either case, further research with these cross-reactive antigens must be undertaken to clarify the actual etiology and mechanisms of the pathology noted.
